Ikena Oncology Inc. (IKNA): P/S Multiple

Symbol and logo of brand ikenaoncology.com (IKNA)

The P/S chart confirms the financial stability of Ikena Oncology, Inc. (IKNA), whose cash reserves fully cover development costs. The current 104.50 reflects the state of the metric amid fierce competition with pharma market behemoths. The absence of profit-generating products forces the company to systematically spend capital on clinical trials, creating a certain degree of operational inertia.

IKNA Ikena Price-to-Revenue Ratio (07/04/2022 - 03/07/2025)

Ikena Oncology Inc. (IKNA) - metric breakdowns and financial figures

- price and consensus price forecast:
Fundamental company analysis:IKNA - Ikena Oncology, Inc.
Signature product of Ikena Oncology

To objectively assess the fundamental value of Ikena Oncology, Inc. (IKNA), investors must analyze the ratio of market capitalization to annual sales. When analyzing the company's current P/S, it should be noted that this ratio measures the market premium to revenue, where rising values signal expectations of breakthrough successes in joint cancer drug developments with academic centers.

Competitors of Ikena Oncology, Inc.

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio CTOR|Price-to-Revenue Ratio TuHURA Biosciences Inc.|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|Price-to-Revenue Coefficient Aadi Bioscience|Price-to-Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Revenue Ratio|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (cel-sci.com)|OSTX: P/S Multiple|Price to Sales Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - P/S Multiple|Market Cap to Revenue Ratio ANL (Adlai Nortye)|Price-to-Revenue Ratio Veru Pharma (VERU)|P/S Multiple Tempest Tx (TPST)|Price-to-Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Revenue Ratio|Mural Oncology - P/S Multiple|KAPA - P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Revenue Ratio|Market Cap to Revenue CytoMed|Price-to-Revenue Ratio curis.com|Market Cap to Revenue Apollomics, Inc. (APLM)|P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Genprex GNPX|Price-to-Revenue Coefficient Calidi Bio (CLDI)|sunshinebiopharma.com - P/S Multiple|Price to Sales xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Revenue Ratio|Purple Biotech Ltd. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio AON|P/S Multiple BeiGene Ltd.|Price-to-Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Market Cap to Revenue Elevation Oncology, Inc. ELEV|P/S Multiple ICAD (iCAD Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd